The First Biosimilar Epoetin: But How Similar Is It?
Cv huub schellekens complet by Ricardo Guerrero - Issuu
Immunogenicity and aggregation of therapeutic proteins - American ...
Clinical comparability and European biosimilar regulations
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
Development of <fc>ADA</fc> Against Recombinant Human Interferon Beta in Immune Tolerant Mice Requires Rapid Recruit
Opgestapt CBG-lid Huub Schellekens uit forse kritiek op 'de perversies van het systeem' - Human - VPRO
Personalised medicine produced in a “Bionexpresso” - News - Utrecht University
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
Webinar: Availability of and Accessibility to Biologics: Implications for Covid and beyond - Public Health Online
eLearning – Biosimilars: From concern to confidence
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
Huub Schellekens | Writers Unlimited
PDF) Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity - Schellekens - 2004 - European Journal of Clinical Investigation - Wiley Online Library
Immunogenicity: The key issue for multisource biologics
EMJ Oncology 6 [Suppl 2] 2018 - European Medical Journal
Huub Schellekens | European Association of Hospital Pharmacists
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
Development of a Transgenic Mouse Model to Study the Immunogenicity of Recombinant Human Insulin
Huub Schellekens – Studium Generale Universiteit Utrecht
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
